Product Code: ETC070127 | Publication Date: Jul 2023 | Updated Date: Jan 2024 | Product Type: Report | |
Publisher: 6Wresearch | No. of Pages: 70 | No. of Figures: 35 | No. of Tables: 5 | |
Orphan drugs are biopharmaceuticals which are used to treat rare diseases or conditions. The Indonesia orphan drug market is growing significantly owing to the rising prevalence of rare diseases, increasing government support for research activities related to orphan drugs, and the presence of a well-established healthcare infrastructure in the country. According to World Health Organization (WHO), around 6% - 8% of people worldwide suffer from some type of rare disease; however, only 5% receive an accurate diagnosis and appropriate treatment due to lack of awareness about these diseases. As such, various initiatives have been undertaken by governments across the world in order to spread awareness about these conditions and encourage medical research for their effective treatments.
The major factors driving growth in Indonesia orphan drug market include increasing regulatory approvals for orphan drugs, government support through financial incentives as well as tax benefits provided by Central Drug Administration (CDA), rising investments from pharmaceutical companies into R&D activities related to orphan drugs, improving healthcare infrastructure in rural areas along with rapidly evolving reimbursement policies pertaining to orphan medicines. Moreover, high unmet needs when it comes to treating certain chronic illnesses coupled with a growing number of collaborations between research institutes and pharmaceutical companies will further propel demand for such medications over the forecast period.
Despite all its potential drivers however , there are several challenges facing Indonesia orphan drug industry . These include low affordability among many patients especially those living in rural regions , limited availability & access due to inadequate distribution networks & logistical issues , limited clinical trials conducted on new compounds & lack of qualified personnel trained on handling them . In addition , patent protection laws remain weakly enforced resulting in generic manufacturers taking advantage creating further competition within this already niche segment.
Major players operating in Indonesia Orphan Drugs Market include PT Sanofi Pasteur MSD Ltd., Novartis AG., Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG etc.. These players offer a wide range of products including vaccines as well as specialty therapies that target certain specific health problems like cancer or AIDS/HIV infections etc.. They also invest heavily into R&D activities so as stay ahead in terms of product innovation which helps them gain competitive edge over others present within same space.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Indonesia Orphan Drugs Market Overview |
3.1 Indonesia Country Macro Economic Indicators |
3.2 Indonesia Orphan Drugs Market Revenues & Volume, 2020 & 2027F |
3.3 Indonesia Orphan Drugs Market - Industry Life Cycle |
3.4 Indonesia Orphan Drugs Market - Porter's Five Forces |
3.5 Indonesia Orphan Drugs Market Revenues & Volume Share, By Drugs, 2020 & 2027F |
3.6 Indonesia Orphan Drugs Market Revenues & Volume Share, By Drug Type, 2020 & 2027F |
3.7 Indonesia Orphan Drugs Market Revenues & Volume Share, By Therapy Class, 2020 & 2027F |
4 Indonesia Orphan Drugs Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Indonesia Orphan Drugs Market Trends |
6 Indonesia Orphan Drugs Market, By Types |
6.1 Indonesia Orphan Drugs Market, By Drugs |
6.1.1 Overview and Analysis |
6.1.2 Indonesia Orphan Drugs Market Revenues & Volume, By Drugs, 2018 - 2027F |
6.1.3 Indonesia Orphan Drugs Market Revenues & Volume, By Revlimid, 2018 - 2027F |
6.1.4 Indonesia Orphan Drugs Market Revenues & Volume, By Rituxan, 2018 - 2027F |
6.1.5 Indonesia Orphan Drugs Market Revenues & Volume, By Opdivo, 2018 - 2027F |
6.1.6 Indonesia Orphan Drugs Market Revenues & Volume, By Keytruda, 2018 - 2027F |
6.1.7 Indonesia Orphan Drugs Market Revenues & Volume, By Imbruvica, 2018 - 2027F |
6.1.8 Indonesia Orphan Drugs Market Revenues & Volume, By Soliris, 2018 - 2027F |
6.2 Indonesia Orphan Drugs Market, By Drug Type |
6.2.1 Overview and Analysis |
6.2.2 Indonesia Orphan Drugs Market Revenues & Volume, By Biologics, 2018 - 2027F |
6.2.3 Indonesia Orphan Drugs Market Revenues & Volume, By Non-Biologics, 2018 - 2027F |
6.3 Indonesia Orphan Drugs Market, By Therapy Class |
6.3.1 Overview and Analysis |
6.3.2 Indonesia Orphan Drugs Market Revenues & Volume, By Oncology, 2018 - 2027F |
6.3.3 Indonesia Orphan Drugs Market Revenues & Volume, By Blood, 2018 - 2027F |
6.3.4 Indonesia Orphan Drugs Market Revenues & Volume, By Endocrine, 2018 - 2027F |
6.3.5 Indonesia Orphan Drugs Market Revenues & Volume, By Central Nervous Systems, 2018 - 2027F |
6.3.6 Indonesia Orphan Drugs Market Revenues & Volume, By Cardiovascular, 2018 - 2027F |
6.3.7 Indonesia Orphan Drugs Market Revenues & Volume, By Respiratory, 2018 - 2027F |
7 Indonesia Orphan Drugs Market Import-Export Trade Statistics |
7.1 Indonesia Orphan Drugs Market Export to Major Countries |
7.2 Indonesia Orphan Drugs Market Imports from Major Countries |
8 Indonesia Orphan Drugs Market Key Performance Indicators |
9 Indonesia Orphan Drugs Market - Opportunity Assessment |
9.1 Indonesia Orphan Drugs Market Opportunity Assessment, By Drugs, 2020 & 2027F |
9.2 Indonesia Orphan Drugs Market Opportunity Assessment, By Drug Type, 2020 & 2027F |
9.3 Indonesia Orphan Drugs Market Opportunity Assessment, By Therapy Class, 2020 & 2027F |
10 Indonesia Orphan Drugs Market - Competitive Landscape |
10.1 Indonesia Orphan Drugs Market Revenue Share, By Companies, 2020 |
10.2 Indonesia Orphan Drugs Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |